{"id":17,"date":"2024-04-03T23:11:00","date_gmt":"2024-04-03T20:11:00","guid":{"rendered":"https:\/\/sisu.ut.ee\/antikehad\/kirjandusallikad\/"},"modified":"2024-04-03T23:11:04","modified_gmt":"2024-04-03T20:11:04","slug":"kirjandusallikad","status":"publish","type":"page","link":"https:\/\/sisu.ut.ee\/antikehad\/kirjandusallikad\/","title":{"rendered":"Kirjandusallikad"},"content":{"rendered":"

Originaalartiklid:<\/strong><\/p>\n

    \n
  1. K\u00f6hler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-7.<\/li>\n
  2. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT (1984). Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 81: 6851-5.<\/li>\n
  3. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G (1986). Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321: 522\u2013525.<\/li>\n
  4. McCafferty J, Griffiths AD, Winter G, Chiswell DJ (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348: 552-4.<\/li>\n
  5. Boder ET, Wittrup KD (1997) Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 15: 553-7.<\/li>\n
  6. Hanes J, Pl\u00fcckthun A (1997) In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci USA 94: 4937-42.<\/li>\n<\/ol>\n

    \u00dclevaateartiklid<\/strong>:<\/p>\n

      \n
    1. Hoogenboom HR (2005) Selecting and screening recombinant antibody libraries. Nat Biotechnol 23: 1105-16. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16151404<\/a><\/li>\n
    2. Lonberg N (2005) Human antibodies from transgenic animals. Nat Biotechnol. 23(9): 1117-25. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16151405<\/a><\/li>\n
    3. Carter PJ (2006). Potent antibody therapeutics by design. Nat Rev Immunol 6 (5): 343-57. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16622479<\/a><\/li>\n
    4. Reichert JM (2008) Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol. 9(6): 423-30. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19075682<\/a><\/li>\n
    5. Nelson AL, Dhimolea E, Reichert JM (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9(10): 767-74 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20811384<\/a><\/li>\n
    6. Beerli RR, Rader C (2010). Mining human antibody repertoires. MAbs (4): 365-378. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20505349<\/a><\/li>\n
    7. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 355 (10): 1018-28. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16908486<\/a><\/li>\n
    8. Weiner LM, Murray JC, Shuptrine CW. Cell (2012) Antibody-based immunotherapy of cancer. 148(6):1081-4. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22424219<\/a><\/li>\n
    9. Reichert JM, Dhimolea E (2012). The future of antibodies as cancer drugs. Drug Discov Today. 17(17-18): 954-63. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22561895<\/a><\/li>\n
    10. Chan AC, Carter PJ (2010) Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 10: 301\u201316. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20414204<\/a><\/li>\n
    11. Beck A, Wurch T, Bailly C, Corvaia N (2010). Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol. 10(5):345-52. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20414207<\/a><\/li>\n<\/ol>\n

      Veebiallikad:<\/strong><\/p>\n

        \n
      1. Eesti ravimiregister: <\/span>http:\/\/193.40.10.165\/register\/register.php?keel=est&inim_vet=inim<\/a><\/li>\n
      2. US Food and Drug Administration:\u00a0<\/span>http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm<\/a><\/li>\n
      3. European medicines agency: <\/span>http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/landing\/epar_search.jsp&mid=WC0b01ac058001d124<\/a><\/li>\n
      4. mAbs, Janice M Reichert: <\/span>http:\/\/www.landesbioscience.com\/journals\/mabs\/about\/<\/a>\u00a0<\/strong><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

        Originaalartiklid: K\u00f6hler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-7. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT (1984). Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. …<\/p>\n","protected":false},"author":280,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-17","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/sisu.ut.ee\/antikehad\/wp-json\/wp\/v2\/pages\/17","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sisu.ut.ee\/antikehad\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/sisu.ut.ee\/antikehad\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/sisu.ut.ee\/antikehad\/wp-json\/wp\/v2\/users\/280"}],"replies":[{"embeddable":true,"href":"https:\/\/sisu.ut.ee\/antikehad\/wp-json\/wp\/v2\/comments?post=17"}],"version-history":[{"count":1,"href":"https:\/\/sisu.ut.ee\/antikehad\/wp-json\/wp\/v2\/pages\/17\/revisions"}],"predecessor-version":[{"id":73,"href":"https:\/\/sisu.ut.ee\/antikehad\/wp-json\/wp\/v2\/pages\/17\/revisions\/73"}],"wp:attachment":[{"href":"https:\/\/sisu.ut.ee\/antikehad\/wp-json\/wp\/v2\/media?parent=17"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}